Merck announced it will discontinue developing an experimental drug combination for chronic hepatitis C, after reviewing mid-stage trial data of the treatments.
Merck made the decision about the new combo treatments (MK-3682B and MK-3682C) after reviewing their effectiveness and considering the crowded Hep C market.
The drugmaker says it will continue to study its approved treatment, Zepatier, to understand even more about its role in treating chronic hepatitis C infection.
Read the press release